ReHealth AI completes Seed Round financing for world's first preventive healthcare closed-loop platform integrating prediction, intervention, attribution, and settlement

ReHealth AI, a preventive healthcare AI company, has completed a 4 million RMB seed round financing at a post-money valuation of 25 million RMB. The investor has not been disclosed. In addition to providing financial support, the investor is also offering deep business-level collaboration. The funds from this round will be used for small-scale clinical retrospective testing, regulatory submission for a Class II medical device software, algorithm and model filing, and the engineering implementation of a complete closed loop encompassing prediction, intervention, propensity score matching (PSM) attribution, and settlement validation.

There are over 330 million patients with cardiovascular and cerebrovascular diseases in China (Report on Cardiovascular Health and Diseases in China 2023), making this the chronic disease category with the largest patient base in the country. Data from the World Health Organization show that 80 percent of cardiovascular and cerebrovascular diseases can be prevented through lifestyle interventions, and improvements in biomarkers can be observed within six months.

However, preventive care investment has long been marginalized within the current healthcare payment system. The fundamental reason is not a lack of awareness, but a lack of infrastructure—healthcare providers cannot quantify intervention outcomes, insurance companies cannot translate prevention results into billable evidence, and government health departments cannot report to decision-makers on whether prevention is actually effective. This structural dilemma constrains the commercialization progress of the entire preventive healthcare industry chain.

ReHealth AI has focused its problem-solving approach on the word "settlement." The team has built a four-module unified platform with "preventive care settlement" as its core objective function. The cardiovascular and cerebrovascular risk prediction module, based on 16 clinical feature dimensions, achieves an Area Under the Curve of 0.84 and can identify high-risk patients one to three years in advance. The personalized intervention plan generation module automatically produces clinical-grade intervention recommendations based on the patient's risk factors. 

The propensity score matching causal inference module uses a quasi-experimental method to construct an intervention group and a control group, eliminating selection bias and quantifying, in statistical terms, whether the intervention has truly reduced risk. The settlement evidence generation module converts causal attribution results into standardized settlement reports that can be audited by insurance companies and healthcare providers.

This platform is currently the world's first cross-disease artificial intelligence platform that directly links preventive attribution results to payment settlement. Most competing products on the market today stop at the prediction or intervention stage and have not closed the loop between attribution and settlement.

At the technical architecture level, the platform adopts a medical-grade federated learning approach. Patient raw data never leaves the hospital, and only model gradients processed with differential privacy are uploaded, meeting the compliance requirements of the Personal Information Protection Law and the Data Security Law. The team has currently filed for four patents and five software copyrights, covering core methodological areas such as multimodal risk prediction, federated learning optimization, health memory graph modeling, and intervention attribution and settlement.

The team has made cardiovascular and cerebrovascular diseases their first breakthrough, providing B-end services to medical institutions, commercial insurance companies, and corporate health management entities. After planning to complete a full commercial closed loop, they aim to horizontally replicate the same infrastructure for high-claim diseases such as diabetes, chronic obstructive pulmonary disease (COPD), and cancer screening. Currently, three medical institutions have entered the substantive negotiation stage.

At the macro policy level, commercial health insurance premiums reached 977.4 billion RMB in 2024, according to the National Financial Regulatory Administration. The trend of insurance companies transforming from payers to health management providers is becoming increasingly clear. The Healthy China 2030 initiative is driving the healthcare system to shift from a treatment-centered model to a health-centered model, and the National Healthcare Security Administration is exploring preventive care payment mechanisms. The simultaneous convergence of technological, policy, and payment conditions constitutes a strategic window of opportunity for ReHealth AI to enter the market.